UNH · Unitedhealth Group Incorporated

The thesis

UnitedHealth Group's margin repair held through the third quarter, and the shares are back near their 52-week high on it. The case now depends on 2027. Medicare enrollment closes on 7 December 2026, and the 2027 earnings outlook is expected in mid-January. Those two events show whether the recovery carries into next year.

On 13 October 2026 the company beat estimates and raised its 2026 outlook for adjusted earnings per share (EPS) to at least $20.50, according to its Form 8-K. Third-quarter adjusted EPS was $4.69, up from $2.92 a year earlier. The medical care ratio (MCR, the share of premiums paid out in claims) improved to 88.4% from 89.9%. On the call, management said its 2027 EPS forecast starts from the lower end of its 13%–16% long-term growth range (Benzinga, 13 October 2026).

The shares closed at $419.26 on 20 October 2026 on adjusted daily closes, up from $406.88 a session earlier. That close is 3.3% below the 52-week high of $433.68. The narrative is maturing: the recovery is widely covered, and target changes since the 13 October 2026 report have gone both ways, most recently RBC Capital's raise to $498 from $478 on 20 October 2026 (Benzinga). Elevance Health's third-quarter report, scheduled for 21 October 2026 at 6:00 a.m. Eastern, is the next test of the industry-wide improvement in medical costs.

Bullish and bearish views on Unitedhealth Group Incorporated

The bull case on Unitedhealth Group Incorporated (UNH), in brief: Guidance has risen twice this year. The bear case: Medical costs rose from the second quarter.

Bull case

• Guidance has risen twice this year. The 13 October 2026 release raised 2026 adjusted EPS guidance to at least $20.50, from the $19.50–$20.00 range set in July. GAAP EPS guidance rose to at least $19.50. Benzinga put the consensus at $19.86 that day, below the new adjusted figure.
• Target raises keep arriving after the report. RBC Capital raised its target to $498 from $478 with an Outperform rating on 20 October 2026 (Benzinga). Morgan Stanley's target is $529 (24/7 Wall St., 14 October 2026), J.P. Morgan's is $524 with an Overweight rating (Benzinga, 16 October 2026) and Piper Sandler's is $504 (Benzinga, 14 October 2026).
• Optum margins widened sharply. Optum operating earnings rose to $3.7 billion from $2.5 billion, and its operating margin reached 5.6% against 3.6% (Form 8-K, 13 October 2026). Optum Health's chief executive called the path to 6%–8% margins a multi-year effort (Benzinga, 14 October 2026).
• The insurance unit's profits recovered. UnitedHealthcare's third-quarter operating earnings rose to $2.8 billion from $1.8 billion (Form 8-K, 13 October 2026). Chief executive Tim Noel said Medicaid margins hit bottom in 2026 and expects them to improve through 2028 (Benzinga, 13 October 2026).
• Cash generation pays for buybacks and dividends. Third-quarter operating cash flow was $5.1 billion, 1.2 times net income. Buybacks totaled $5.0 billion and dividends $6.2 billion for the year to date (Form 8-K, 13 October 2026).

Bear case

• Medical costs rose from the second quarter. The third-quarter MCR of 88.4% compares with 86.7% in the second quarter of 2026. Favorable prior-period reserve development fell to $610 million from $860 million, and management said care intensity remains above historical norms (Benzinga, 13 October 2026).
• Lower star ratings threaten 2028 revenue. TD Cowen analyst Ryan Langston estimated that lower Medicare Advantage star ratings could cost about $1.5 billion of revenue in 2028, per MoneyCheck. J.P. Morgan estimated that the share of members in plans rated four stars or better falls to about 67% for 2027 from about 81% (TIKR, 10 October 2026).
• Some targets sit below the price. TD Cowen reiterated Hold with a $402 target on 15 October 2026, and Baird cut its target to $427 from $453 on 14 October 2026 (Benzinga). Both sit close to or below the $419.26 close on 20 October 2026.
• Revenue is no longer growing. Third-quarter revenue was $112.7 billion against $113.2 billion a year earlier, and Medicare Advantage membership fell 935,000 from year-end 2025 (Form 8-K, 13 October 2026). Profit growth rests on margins while the member base shrinks.
• Investigations remain open. Department of Justice criminal and civil inquiries into Medicare Advantage practices have no disclosed resolution. Texas Attorney General Ken Paxton opened a state investigation into coverage denials on 5 October 2026.

Price setup

The shares closed at $419.26 on 20 October 2026, 3.3% below the 52-week high of $433.68, on adjusted daily closes. Over three months the shares are down 0.4%, so the post-earnings rally has recovered ground lost earlier rather than set new highs. The 30 September 2026 close of $367.08 marks where the rally began.

Crowding signs are visible. The 14-day relative strength index stood at 80.8 on 20 October 2026, above the 70 level conventionally read as overbought. UnitedHealth appeared in CNBC Halftime Report "Final Trades" on both 19 October 2026 and 20 October 2026, and fund manager Kevin Simpson said on CNBC on 20 October 2026 that he had bought more shares. Health care led the sector tables on 14 October 2026, 15 October 2026 and 20 October 2026 while technology trailed (Benzinga), so part of the move reflects a defensive rotation across the sector.

Catalysts, next 30 days

• ~4 November 2026, est. UnitedHealth third-quarter Form 10-Q. Updates reserve, litigation and investigation disclosures, including any reserve tied to the federal or Texas inquiries.
• 6 November 2026 — Humana third-quarter results. A Medicare Advantage–heavy peer whose commentary on 2027 enrollment and star ratings bears directly on UnitedHealthcare.
• 7 December 2026 — Medicare annual enrollment closes (opened 15 October 2026). Sets how many members choose UnitedHealthcare plans for 2027 under lower star ratings.
• ~15 January 2027, est. Fourth-quarter report and 2027 outlook. The event the case turns on: whether 2027 EPS guidance starts at or above the lower end of the 13%–16% range, and whether the MCR holds without reserve releases.

Elapsed catalysts

• 21 October 2026, 6:00 a.m. Eastern — Elevance Health third-quarter 2026 results. The first large peer report after UnitedHealth's. Its Medicare Advantage and Medicaid cost trends test whether the industry-wide improvement holds. Alphastreet put the consensus at $4.69 EPS on $49.16 billion of revenue. (passed 1d ago)

What would change the view

The operating case breaks if 2027 adjusted EPS guidance lands below the lower end of the 13%–16% long-term growth range, which management named as the starting point on the 13 October 2026 call. A fourth-quarter MCR above 88.4% with little favorable reserve development would show the cost improvement leaned on one-time releases. A 2027 Medicare Advantage membership decline larger than 2026's 935,000, or a charge, settlement or reserve tied to the Department of Justice or Texas inquiries, would also weaken the case.

On price, a daily close below $355 would sit under the 30 September 2026 close of $367.08 and erase the entire post-earnings rally. Weak cost trends at Elevance on 21 October 2026 or Humana on 6 November 2026 would raise the odds of that move before UnitedHealth reports again.

What it trades with

UnitedHealth trades with the managed-care group, chiefly Elevance Health, Humana and CVS Health, because Medicare Advantage rate notices, star ratings and medical cost trends hit all of them at once. Peer reports on 21 October 2026 and 6 November 2026 are likely to move the shares even without company news. In mid-October the stock also traded as a defensive holding: health care led on days when technology fell after the hotter-than-expected September consumer price report on 14 October 2026 (Benzinga). A recovery in technology could pull money back out of the sector regardless of UnitedHealth's own results.